GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Medline MDLN · USD

Health Care · US listing · 🇺🇸 United States

Compare

40.71

+2.70%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$28.43bn

FY2022FY2025

Net income

$1.16bn

FY2022FY2025

Free cash flow

$1.30bn

FY2022FY2025

Shareholders' equity

$10.74bn

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue$28.43bn$25.51bn$23.23bn$21.45bn
Gross profit$7.52bn$6.29bn$5.22bn$4.56bn
Research and development—$67.0m$60.0m$58.0m
Operating income$2.21bn$2.23bn$1.44bn$870.0m
Net income$1.16bn$1.20bn$234.0m−$25.0m
Diluted earnings per share1.431.480.30-0.03

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets$38.48bn$35.98bn$36.12bn—
Cash and short-term investments$1.94bn$250.0m$1.58bn—
Total liabilities$19.20bn$19.45bn$19.14bn—
Debt$12.56bn$16.49bn$16.52bn—
Shareholders' equity$10.74bn$16.52bn$16.98bn—
Shares outstanding812m812m787m787m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations$1.74bn$1.77bn$1.69bn$187.0m
Capital spending−$447.0m−$364.0m−$285.0m−$254.0m
Free cash flow$1.30bn$1.41bn$1.40bn−$67.0m
Dividends paid−$518.0m—−$114.0m—

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Sept 2024Jun 2024
Revenue$7.68bn$7.35bn$7.79bn$7.12bn$6.89bn$6.64bn$6.39bn$6.18bn
Gross profit$2.21bn$1.67bn$1.91bn$1.88bn$1.73bn$1.82bn$1.58bn$1.49bn
Operating income$395.0m$422.0m$425.0m$574.0m$629.0m$571.0m$574.0m$516.0m
Net income$60.0m$129.0m$180.0m$322.0m$333.0m$322.0m$324.0m$292.0m
Diluted earnings per share0.070.150.220.250.410.250.400.36
Cash from operations$715.0m$412.0m$229.0m$636.0m$243.0m$636.0m$722.0m—
Capital spending−$111.0m−$96.0m−$342.0m−$101.0m−$140.0m−$101.0m−$107.0m—
Free cash flow$604.0m$316.0m−$113.0m$535.0m$103.0m$535.0m$615.0m—
Total assets$39.35bn$39.01bn$38.48bn$36.88bn$36.43bn———
Cash and short-term investments$2.68bn$2.24bn$1.94bn$952.0m$584.0m$278.0m——
Debt$12.64bn$12.64bn$12.56bn$16.50bn$145.0m———
Shareholders' equity$11.57bn$11.27bn$10.74bn$17.14bn$16.95bn$16.16bn——

Financial ratios

Data as of 15 Sept 2026

FY2025FY2024FY2023FY2022
Gross margin26.4%24.7%22.5%21.2%
Operating margin7.8%10.0%7.1%4.3%
Net margin4.1%4.7%1.0%-0.1%
Return on equity10.8%7.3%1.4%—
Return on assets3.0%3.3%0.6%—
Free cash flow yield8.3%8.1%——
Revenue growth11.5%9.8%8.3%—
Earnings growth-3.4%412.8%-1036.0%—
Current ratio4.29x3.39x4.13x—
Debt to equity1.17x0.01x0.01x—
Equity ratio27.9%45.9%47.0%—
Interest coverage2.72x1.95x1.19x1.01x
R&D as a share of sales—0.3%0.3%0.3%
Buybacks as a share of market value0.0%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue9.9%——
Operating income36.5%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin25.6%23.9%——

Valuation history

At each fiscal year end

FY2025
Price to earnings29.4
Price to sales1.2

Market value over time

28 Nov 2025 to 14 Sept 2026, in USD

$46.44bn$28.06bn

Share price return

Finished calendar years

2025
Return-4%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.